Page last updated: 2024-08-18

4-butyrolactone and Dermatitis, Atopic

4-butyrolactone has been researched along with Dermatitis, Atopic in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Luo, J; Sun, L; Wang, P; Xu, Q; Yu, L; Zhang, L; Zheng, Z; Zhou, J; Zuo, D1

Other Studies

1 other study(ies) available for 4-butyrolactone and Dermatitis, Atopic

ArticleYear
Secoisolariciresinol diglucoside-derived metabolite, enterolactone, attenuates atopic dermatitis by suppressing Th2 immune response.
    International immunopharmacology, 2022, Volume: 111

    Topics: 4-Butyrolactone; Animals; Anti-Inflammatory Agents; Butylene Glycols; Child, Preschool; Dermatitis, Atopic; Dinitrochlorobenzene; Glucosides; Humans; Immunity; Lignans; Mice; Mice, Inbred BALB C; Skin

2022